Capricor Therapeutics Inc (NASDAQ:CAPR) Short Interest Update

Capricor Therapeutics Inc (NASDAQ:CAPR) saw a significant increase in short interest in the month of December. As of December 15th, there was short interest totalling 5,590,000 shares, an increase of 26.8% from the November 30th total of 4,410,000 shares. Based on an average daily trading volume, of 3,570,000 shares, the short-interest ratio is currently 1.6 days.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on CAPR shares. Cantor Fitzgerald lifted their price target on Capricor Therapeutics from $25.00 to $30.00 and gave the company an “overweight” rating in a report on Thursday, November 14th. Piper Sandler initiated coverage on Capricor Therapeutics in a research note on Monday, October 21st. They issued an “overweight” rating and a $35.00 target price on the stock. Maxim Group increased their price target on shares of Capricor Therapeutics from $12.00 to $25.00 and gave the company a “buy” rating in a research report on Wednesday, September 25th. Oppenheimer reaffirmed an “outperform” rating and issued a $15.00 price objective on shares of Capricor Therapeutics in a research report on Monday, September 23rd. Finally, HC Wainwright reiterated a “buy” rating and set a $77.00 price objective on shares of Capricor Therapeutics in a research note on Thursday, November 14th. One research analyst has rated the stock with a sell rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, Capricor Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $34.50.

Capricor Therapeutics Stock Performance

Capricor Therapeutics stock opened at $13.76 on Tuesday. The stock has a market cap of $625.67 million, a PE ratio of -12.98 and a beta of 3.98. The stock has a 50-day moving average of $17.23 and a two-hundred day moving average of $10.70. Capricor Therapeutics has a one year low of $3.52 and a one year high of $23.40.

Hedge Funds Weigh In On Capricor Therapeutics

Several hedge funds have recently modified their holdings of CAPR. Main Street Financial Solutions LLC increased its stake in Capricor Therapeutics by 37.5% during the 2nd quarter. Main Street Financial Solutions LLC now owns 27,500 shares of the biotechnology company’s stock valued at $131,000 after purchasing an additional 7,500 shares in the last quarter. SG Americas Securities LLC purchased a new stake in shares of Capricor Therapeutics during the third quarter valued at $133,000. Bank of New York Mellon Corp grew its holdings in shares of Capricor Therapeutics by 12.8% during the second quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company’s stock valued at $381,000 after buying an additional 9,040 shares during the last quarter. The Manufacturers Life Insurance Company acquired a new position in shares of Capricor Therapeutics in the 3rd quarter valued at $161,000. Finally, Sassicaia Capital Advisers LLC purchased a new position in Capricor Therapeutics in the 3rd quarter worth $192,000. Institutional investors and hedge funds own 21.68% of the company’s stock.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.